August 2016 in “PolyPublie (École Polytechnique de Montréal)” Doxorubicin causes heart damage, so early detection and monitoring are important during chemotherapy.
9 citations
,
April 2018 in “JAMA Dermatology” Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
Belimumab effectively controls SLE disease activity and reduces steroid use.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” 2 citations
,
January 2014 in “Journal of Cytology & Histology” Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
A new 3D breast tumor model helps test drug effects more accurately than traditional methods.
December 2024 in “International Journal of Molecular Sciences” Platelet-rich fibrin may help reduce nonmelanoma skin cancer cell growth.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
November 2025 in “Journal of Investigative Dermatology”
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology”
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.
July 2021 in “British Journal of Dermatology” Laser treatment for skin conditions VEN and ILVEN is effective and liked by patients.
2 citations
,
September 2020 in “International journal of radiology & radiation therapy” Radiotherapy can cause rare changes in hair color, which should be discussed with patients.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
January 2023 in “Cancer research, statistics, and treatment/Cancer research, statistics and treatment” Vijaya successfully fought stage 2A breast cancer with surgery, chemotherapy, radiotherapy, and hormone therapy, while advocating for support groups.
4 citations
,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
11 citations
,
October 2019 in “Journal of Cancer Immunology” Combining Proton Minibeam with FLASH Radiotherapy may improve cancer treatment by reducing side effects and increasing effectiveness.
March 2005 in “Journal of the American Academy of Dermatology” Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
February 2026 in “Libri Oncologici Croatian Journal of Oncology” Imiquimod shows promise as a non-invasive treatment for certain HPV-related lesions, but more research is needed to optimize its use.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.